Optimizing the use of BEtaloc ZOK in patients with CHF in routine medical practicE. Design and results of the study BEZE

Rate of BAB prescription to patients with CHF has remained low, especially among general practitioners. Only 9% of Russian patients have received prescribed β-adrenoblockers (BAB) (Betaloc ZOK, bisoprolol and carvedilol). Taking into account the reluctance to prescribing recommended BAB to patients with CHF, the first Russian multicenter, open-label study was performed in a real outpatient setting. The study was named «Optimizing the use of BEtaloc ZOK in patients with CHF in routine medical practicE (BEZE)». It was aimed at studying safety and efficacy of Betaloc ZOK in multimodality treatment of CHF and teaching physicians how to use tools for control over the condition in patients with CHF in real practice. A totality of 1427 patients with CHF was evaluated. It was shown that treatment of CHF with Betaloc ZOK even at low doses in the outpatient setting was not associated with clinical impairment in the first weeks, i.e. the drug was efficient and safe. Betaloc ZOK is an optimum choice for treatment of both systolic CHF and AH and diastolic dysfunction complicated with symptoms of cardiac decompensation.